GlassScriptPhysician profile
Nakul Goyal
NPI 1194738567
$2,302.46
in general payments reported to CMS, 2019-2025
21 companies · $92.97 in 2025
The $92.97 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $104 · 2021: $293 · 2022: $515 · 2023: $389 · 2024: $208 · 2025: $92.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.12 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $363.79 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $300.35 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.06 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $106.20 | 2019-2021 | |
| Amgen INC. | $104.38 | 2019-2023 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $95.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $88.59 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $85.17 | 2019-2023 | Xarelto |
| Abbvie INC. | $74.33 | 2023-2025 | |
| Incyte Corporation | $72.79 | 2022-2024 | Opzelura |
| Merck Sharp & Dohme LLC | $50.64 | 2019-2021 | |
| Abbott Laboratories | $50.35 | 2021-2022 | |
| Lilly USA, LLC | $49.72 | 2019-2022 | |
| Janssen Biotech, INC. | $46.47 | 2022-2025 | Tremfya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $22.76 | 2024 | Zoryve |
| Vifor Pharma, INC. | $20.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.46 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $11.74 | 2019 | |
| Allergan, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakul Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.